Trastuzumab

Product Name: Trastuzumab

Synonyms: Herceptin;TrastuzuMab(Herceptin);TRASTUZUMAB 98 % +;IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer;TRASTUZUMAB 95 % +;Anti HER2, Ig gamma-1 chain C region;Trastuzumab - 20mg/ml in PBS;Recombinant humanized anti-HER2 antibody

CAS: 180288-69-1

MF: C10H14N6O5

MW: 298.25536

EINECS:

Product Categories: -

Mol File: 180288-69-1.mol

Trastuzumab Structure

Trastuzumab Chemical Properties

Safety Information

MSDS Information

Trastuzumab Usage And Synthesis

Indications The introduction of herceptin (Trastuzumab) into clinical practice for the treatment of breast cancer marks a major advance in the use of monoclonal antibody cancer therapy. Herceptin is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. HER-2/neu/erbB2 overexpression marks an aggressive estrogen receptor–negative form of breast cancer. Therefore, a therapeutic agent selective for this target is particularly valuable. Herceptin is administered by intravenous infusion and in conjunction with paclitaxel can extend survival in patients with HER-2/neu/erbB2 overexpressing metastatic breast cancer.Herceptin use is associated with infusion- related hypotension, flushing and bronchoconstriction, and skin rash but no bone marrow toxicity. Herceptin appears to sensitize patients to cardiotoxicity, an important concern in patients also receiving doxorubicin.